Titan Biotech — 360° view

Titan Biotech, a company in the Specialty Chemicals industry, reported revenue of ₹76 crore and net profit of ₹13 crore for the September 2026 quarter.

Titan Biotech (BSE: TITANBIO) closed at ₹381.10 on 20 Nov 2026, up 100.3% over the past year. Its market capitalisation is ₹1,968 crore and it trades at 50.9 times earnings.

Share price
₹381.10 (20 Nov 2026)
Market cap
₹1,968 Cr (20 Nov 2026)
P/E
50.90 (20 Nov 2026)
Revenue
₹76 Cr (September 2026 quarter)
Net profit
₹13 Cr (September 2026 quarter)
ROCE
22.8% (FY26)
ROE
17.8% (FY26)
Book value
₹39.3 (FY26)
Dividend yield
0.11% (FY26)
52-week high / low
₹555.65 / ₹171.40 (20 Nov 2026)
1-year return
100.3% (to 20 Nov 2026)
Sector
Commodities
Industry
Specialty Chemicals
Symbol
BSE: TITANBIO

Incorporated in 1992, Titan Biotech Ltd manufacturer and exporter of the Biological products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.